Notícias e Atividades da Apellis Pharmaceuticals

Apellis Pharmaceuticals é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Apellis Pharmaceuticals é uma empresa listada sob o símbolo APLS (US).

Veja o organograma con seus 23 executivos principais

Biografias mais buscadas da Apellis Pharmaceuticals

• Cedric Francois, Chief Executive Officer and Director
• Gerald Chan, Chairman of the Board
• Stephanie Monaghan O'Brien, Director

Recentes movimentos de executivos em Apellis Pharmaceuticals

• Keli Walbert, ingressou na Companhia como Director  (Notícia publicada em 13 de janeiro de 2025).

Criar um alerta
para seguir os movimentos de executivos da Apellis Pharmaceuticals.

Apellis Pharmaceuticals possui 2.350 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Johnson & Johnson Innovative Medicine DIA (Estados Unidos).

Popular M&A news in Biotecnologia

• Transcarent and Accolade have merged  (publicado em 9 de abril de 2025)..
• Kashiv BioSciences acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 7 de abril de 2025).
• Atsena Therapeutics acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 4 de abril de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Kristina Burow - Director da Scholar Rock
• Steven Gillis - Chairman of the Board da VBI Vaccines
• Ali Behbahani - Non-Executive Director da Adaptimmune Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Apellis Pharmaceuticals

• Apellis Announces 18-Month Data from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy (GA) | Apellis Pharmaceuticals, Inc.
• Apellis Announces New Data Demonstrating Correlation between Complement Activation and COVID-19 Severity | Apellis Pharmaceuticals, Inc.
• Apellis to Present Positive Results from the Phase 2 DISCOVERY Study of Pegcetacoplan in C3 Glomerulopathy (C3G) at ASN Kidney Week | Apellis Pharmaceuticals, Inc.
• Apellis Initiates Registrational Programs of Pegcetacoplan in Patients with C3G / IC-MPGN and ALS, Rare Diseases with High Unmet Need | Apellis Pharmaceuticals, Inc.
• Apellis Announces New Analysis Demonstrating Targeted C3 Therapy Pegcetacoplan Slows Progression of Early Disease in Patients with Geographic Atrophy (GA) | Apellis Pharmaceuticals, Inc.
• Apellis Pharmaceuticals to Present at Stifel’s 2020 Immunology and Inflammation Virtual Summit | Apellis Pharmaceuticals, Inc.
• Apellis Announces Late-Breaking Presentation of Targeted C3 Therapy Pegcetacoplan in Patients with Geographic Atrophy (GA) at EURETINA 2020 | Apellis Pharmaceuticals, Inc.
• Apellis Announces Submission of Pegcetacoplan Marketing Applications to FDA and EMA for Patients with PNH | Apellis Pharmaceuticals, Inc.
• Apellis Pharmaceuticals to Present at Upcoming Investor Conferences | Apellis Pharmaceuticals, Inc.
• Apellis Pharmaceuticals Reports Second Quarter 2020 Financial Results | Apellis Pharmaceuticals, Inc.
• View more press releases Close

Redes sociais sobre Apellis Pharmaceuticals

• Apellis Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
• Apellis Pharmaceuticals na LinkedIn, Twitter e YouTube